AR and heart failure: Our research group, as well as others, have shown that in addition to the endogenous β1-AR ligand norepinephrine (NE), autoantibodies against β1-AR (β1-AA), with agonist-like effects, circulate in the sera of 40–60% of heart failure patients [7, 63].